Investigating how purinergic signaling affects blood vessel health in autoimmune diseases
Purinergic modulation of the autoimmune vascular phenotype
This study is looking at how certain signals in the body affect blood vessel function in people with antiphospholipid syndrome (APS), with the hope of finding new treatments to help manage the condition better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11001220 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of purinergic signaling in autoimmune conditions, particularly in patients with antiphospholipid syndrome (APS). It aims to explore how this signaling pathway influences blood vessel function and contributes to thrombotic events, which are common in APS. By studying a carefully selected group of patients and using advanced laboratory techniques, the researchers hope to identify new therapeutic approaches that could improve treatment outcomes for APS patients. The ultimate goal is to find promising drug candidates that can be repurposed for clinical use in managing APS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with antiphospholipid syndrome, particularly those who have experienced thrombotic events despite standard anticoagulant therapy.
Not a fit: Patients without a diagnosis of antiphospholipid syndrome or those who do not experience thrombotic events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce the risk of blood clots and improve overall vascular health in patients with autoimmune diseases.
How similar studies have performed: Previous research has shown promise in exploring purinergic signaling in other contexts, but this specific approach in APS is relatively novel and untested.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Knight, Jason — University of Michigan at Ann Arbor
- Study coordinator: Knight, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.